Global Antihyperlipidemic Drugs Market: Overview
Hyperlipidemia also referred to as hyperlipoproteinemia, is a lipid condition characterized by elevated lipid (fat) levels in the blood. It's caused by a problem with lipid metabolism, a problem with plasma lipoprotein production & breakdown, or a plasma lipid transport. Hyperlipidemia is a serious medical problem that must be addressed. Lipid-lowering medications also called cholesterol-lowering, or antihyperlipidemic drugs, are a class of drugs that are used to lower high blood levels of lipids (fats) and lipoproteins (fats containing protein). These medicines are meant to treat cardiovascular disorders such as atherosclerosis and reduce the risk of heart attacks.
Report Scope:
Report Attribute | Details |
---|---|
Base Year | 2020 |
Historic Years | 2016 - 2020 |
Forecast Years | 2021 - 2028 |
Segments Covered | By Product Type, By Application, and By End Use |
Forecast Units | Value (USD Billion), and Volume (Units) |
Quantitative Units | Revenue in USD million/billion and CAGR from 2021 to 2028 |
Regions Covered | North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World |
Countries Covered | U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others |
Number of Companies Covered | 10 companies with scope for including additional 15 companies upon request |
Report Coverage | Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis. |
Customization Scope | Avail customized purchase options to meet your exact research needs. |
Global Antihyperlipidemic Drugs Market: Growth Factors
The global antihyperlipidemic drugs market is fueling at a speedy rate. The prime factor contributing to the growth of the market is the rise in cases of hyperlipidemia and cardiovascular diseases. CVD is the world's leading cause of mortality. In 2019, 17.9 million individuals died from cardiovascular disease (CVD), accounting for 32% of all deaths worldwide. Heart attacks and strokes were responsible for 85 percent of these fatalities. CVD is also the biggest cause of mortality in Europe, responsible for 47 percent of women's deaths and 39 percent of men's deaths. Furthermore, according to a survey by faculty members at the University Putra Malaysia's Department of Nutrition and Health Sciences, cardiovascular diseases are anticipated to cause seven out of every ten fatalities in developing countries by 2020. This is leading to the huge demand for antihyperlipidemic drugs, thereby driving the market growth. In addition to this, an increase in sedentary lifestyle, rise in healthcare expenditure, and rise in geriatric population are also some of the key factors that are driving the global market. Furthermore, in the near future, significant research and development of antihyperlipidemic combination drugs is expected to boost the global antihyperlipidemic drugs market. However, the increased cost of therapy, as well as strict government rules and laws around medication patents, may limit the global antihyperlipidemic drugs market growth.
COVID-19 was formerly assumed to be a virus that only affected the lungs, but it has now been shown that it may also affect and damage the heart, posing a higher risk of consequences for the many individuals worldwide who already have or are at risk of heart disease. Cardiovascular problems are common in COVID-19 patients, and these, together with pre-existing cardiovascular comorbidities and RF, may lead to severe clinical outcomes and death. Clinicians all across the globe should be aware of this link in order to identify patients who are at higher risk. In the projection period, the increased prevalence of illness among CVD patients would fuel the rise of antihyperlipidemic drugs.
Global Antihyperlipidemic Drugs Market: Segmentation
The global antihyperlipidemic drugs market is bifurcated based on the route of administration, drug class, distribution channel, and region. Based on the route of administration, the global market is divided into intravenous and oral. Cholesterol absorption inhibitors, bile acid sequestrants, statins, combination, PCSK9 inhibitors, and fibric acid derivatives are the drug class of antihyperlipidemic drugs. The distribution channel segment is classified into online retailers, retail stores, and hospital pharmacies.
Global Antihyperlipidemic Drugs Market: Regional Analysis
In terms of revenue, North America is anticipated to lead the global antihyperlipidemic drugs market, and this trend is expected to continue over the projected period. The market for antihyperlipidemic drugs in North America is expected to grow as the frequency of vascular disorders and the number of amputations in the area rise. North American market expansion may also be ascribed to significant expenditures in R&D and healthcare spending by governments and commercial companies in the prosthetics industry in the area. In terms of market share for antihyperlipidemic drugs, Europe is expected to hold the second position in the market. This is owing to mandatory medical insurance in nations like France and Germany, as well as significant disposable income and considerable R&D activity in the region's healthcare industry.
Global Antihyperlipidemic Drugs Market: Competitive Players
Biotest AG, Shire Plc, Pfizer, Inc., Grifols S.A., AstraZeneca plc, Talecris Biotherapeutics, Inc, Baxalta Incorporated, Kedrion S.p.A., Octapharma AG, and Boehringer Ingelheim GmbH are the dominating players that are functioning in the global antihyperlipidemic drugs market.
Global Antihyperlipidemic Drugs Market: Regional Segment Analysis
What Reports Provides
Request the coronavirus impact analysis across industries and markets
The global antihyperlipidemic drugs market is fueling at a speedy rate. The prime factor contributing to the growth of the market is a rise in cases of hyperlipidemia and cardiovascular diseases. In addition to this, an increase in sedentary lifestyle, rise in healthcare expenditure, and rise in geriatric population are also some of the key factors that are driving the global market. Furthermore, in the near future, significant research and development of antihyperlipidemic combination drugs is expected to boost the global antihyperlipidemic drugs market.
Biotest AG, Shire Plc, Pfizer, Inc., Grifols S.A., AstraZeneca plc, Talecris Biotherapeutics, Inc, Baxalta Incorporated, Kedrion S.p.A., Octapharma AG, and Boehringer Ingelheim GmbH are the dominating players that are functioning in the global antihyperlipidemic drugs market.
In terms of revenue, North America is anticipated to lead the global antihyperlipidemic drugs market, and this trend is expected to continue over the projected period. The market for antihyperlipidemic drugs in North America is expected to grow as the frequency of vascular disorders and the number of amputations in the area rise.
Zion Market Research
Tel: +1 (844) 845-5245
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No 020-46277770
US OFFICE NO +1 (844) 845-5245
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed